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Abstract (100 words) 
Neutrophil extracellular traps (NETs) trap and kill pathogens very efficiently 
but also activate dendritic cells and prime T cells. Previously, we 
demonstrated that neutrophils are primed and circulating NETs are elevated 
in relapsing remitting multiple sclerosis (RRMS), a T cell-mediated 
autoimmune disease. Here, we demonstrate gender specific differences in 
circulating NETs but not in neutrophil priming in RRMS patients. Although the 
results from our systematic and in depth characterization of these patients 
argue against a major role of circulating NETs in this disease, they suggest 
that NETs may underlie gender-specific differences in MS pathogenesis. 
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1-Introduction 
The main function of the innate immune system during infection is to eliminate 
the pathogen, and neutrophils are key players in innate immune responses. 
Women of reproductive age are more resistant to sepsis and subsequent 
morbidity and mortality than men (Schroder et al., 1998),  and the incidence of 
sepsis in postmenopausal women increases to levels almost equal to those 
seen in age-matched men (Martin et al., 2003). Women also have a higher 
systemic neutrophil count compared with men (Bain and England, 1975a), 
and neutrophil counts correlate with estradiol levels during menstruation (Bain 
and England, 1975b) and pregnancy (Efrati et al., 1964) suggesting that sex 
hormones influence neutrophilia and overall resistance to sepsis most likely 
by delaying apoptosis in neutrophils (Molloy et al., 2003). In order to eliminate 
pathogens during infections, neutrophils are armed with a variety of weapons 
including engulfment and intracellular degradation of microbes (Hampton et 
al., 1998; Segal, 2005), release of oxygen species and granule proteins 
(Lehrer and Ganz, 1999) and release of extracellular chromatin fibers bound 
to granular, nuclear and cytoplasmic proteins called neutrophil extracellular 
traps (NETs) (Brinkmann et al., 2004). NETs not only trap and kill pathogens 
very efficiently but also minimize collateral tissue damage by containing 
proteases to the DNA fibers and act as physical barriers preventing microbial 
spread. Despite the well documented importance of NETs as an effective 
antimicrobial first line defense mechanism, there is increasing evidence that 
NETs occur in various clinical settings in the absence of microbial infections 
and that they are probably also associated with pathophysiological conditions 
(Amulic et al., 2012; Logters et al., 2009). NETosis, the process of neutrophil 
cell death that leads to expulsion of NETs, can be triggered by different stimuli 
including pro-inflammatory cytokines such as IL-8 and TNFα, phorbol 12-
myristate 13-acetate (PMA) (Brinkmann et al., 2004; Fuchs et al., 2007), 
activated platelets (Clark et al., 2007) and endothelial cells (Gupta et al., 
2010), and placental microparticles (Gupta et al., 2005). In addition to their 
bactericidal potential, NETs can also activate plasmacytoid- (pDCs) (Garcia-
Romo et al., 2011; Lande et al., 2011) and myeloid (mDC) (Sangaletti et al., 
2012) dendritic cells and in consequence modulate inflammatory responses. 
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The activation of DCs by NETs appears to play an important role in the 
pathogenesis of some autoimmune diseases such as psoriasis (Lande et al., 
2007), systemic lupus erythematosus (SLE) (Barrat et al., 2005; Garcia-Romo 
et al., 2011; Lande et al., 2011; Means et al., 2005) small vessel vasculitis 
(Sangaletti et al., 2012) and type I diabetes (Diana et al., 2013). NETs-
activated pDCs produce large amounts of interferon that can lead to the 
maturation of myeloid DCs (mDCs) and exert an effect on T cell function. In 
SLE, pathogenic auto-antibodies have been associated with abnormal 
clearing of NETs and NETosis that results in abnormally high production 
and/or low degradation of NETs, which then leads to tissue damage and 
facilitated generation of large quantities of auto-antibodies creating a vicious 
cycle (Knight and Kaplan, 2012). In small vessel vasculitis, NETs can favor 
neutropil proteins uploading into mDCs and the induction of anti-neutrophil 
cytoplasmic antibodies (ANCAs) (Sangaletti et al., 2012). Recently, we 
demonstrated that NETs are also able to directly prime T cells by reducing 
their activation threshold, which represents a novel link between innate and 
adaptive immune responses (Tillack et al., 2012). 
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating disease of 
the central nervous system with aspects of secondary neurodegeneration 
(Sospedra and Martin, 2005). There are two major forms of MS, relapsing-
remitting (RR)-MS, which affects around 85%-90% of patients, and primary 
progressive (PP)-MS in around 10%-15%. Most RR-MS patients later develop 
secondary progressive (SP)-MS. It is not clear at present, which factors are 
responsible for the different courses. RRMS affects women about twice as 
often as men, while no gender differences are observed in PPMS. The 
activation of CD4+ autoreactive T cells and their differentiation into a T-helper 
type 1 (Th1) phenotype is a crucial event both in the initial phase and in the 
long-term evolution of RRMS. Damage of the central nervous system is 
however, most likely mediated by antibodies, complement, CD8+ T cells, and 
factors produced by innate immune cells. Deregulation in other immune 
networks involving T-helper 2 (Th2) cells, regulatory CD4+ T cells or NK cells 
are probably also involved. Compared to T cell- and antibody responses or to 
other innate immune cells such as DCs and monocytes, the role of neutrophils 
Circulating NETs in MS patients 
 5 
in MS has not been examined extensively. In a previous study (Naegele et al., 
2012), we demonstrated that neutrophils in RRMS patients are more 
numerous and exhibit a primed state. Furthermore we found higher levels of 
NETs in serum from these patients. Gender specific differences were not 
addressed in this study. The chronic inflammatory environment in RRMS 
(Lund et al., 2004) probably underlies this inappropriate neutrophil priming, 
which may result in enhanced neutrophil activation during infection. The 
higher levels of NETs in serum might also be linked to the chronic 
inflammatory environment in MS, but may have been caused by other triggers 
such as infections, that have been associated with relapses in these patients 
(Granieri et al., 2001) or higher frequency of activated platelets (Sheremata et 
al., 2008) or endothelial cells (Minagar et al., 2001) both elevated in MS. Due 
to the central role of T cells in RRMS and the ability of NETs to modulate T 
cell immunity, an abnormally gender-specific high level of NETs in this 
disease as consequence of neutrophil priming may play an important role in 
certain aspects of the pathogenesis and also explain some gender-specific 
differences. 
Here, we have analyzed in detail a large cohort of MS patients including those 
with subforms other than RRMS, and we have found that only a subset of 
RRMS patients shows elevated circulating NETs. We also examined whether 
the higher levels of NETs as well as the primed state of neutrophils in these 
patients show sex differences, and our results indeed indicate that gender 
specific differences exist with respect to levels of circulating NETs but not in 
neutrophil priming. Further, we have performed a systematic and in depth 
characterization of these patients aimed to identify NETs triggers as well as 
their putative role in MS pathogenesis. The results argue against a major role 
of circulating NETs in MS but suggest that NETs may underlie gender-specific 
differences in MS pathogenesis. 
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2-Material and Methods 
2.1 Patients 
Patients were recruited from the inims outpatient clinic and day hospital at the 
University Medical Center Hamburg-Eppendorf. MS diagnosis was based on 
the revised McDonald criteria (Polman et al., 2005). Patients, who had not 
received steroids for at least 4 weeks prior to enrolment or any 
immunomodulatory or immunosuppressive agent during the last 3 months, 
were considered untreated and included in the study. Patients were classified 
into the following MS subgroups: patients with a first demyelinating event 
suggestive of MS, termed clinically isolated syndrome (CIS, n=126), RRMS 
(n=168) and PPMS (n=21). The CIS and RRMS group included patients that 
were either neurologically stable for at least 30 days before sampling 
(remission state, CIS n=76 and RRMS n=99) or exhibited an acute episode of 
neurological worsening lasting for more than 24 h at the time of sampling and 
not having received steroids (relapse state, CIS n=50 and RRMS n=69). 
Patients did not show clinical signs or symptoms of acute infection. Controls 
included patients with inflammatory neurological disease other than MS 
(OIND, n=5), patients with other non-inflammatory neurological diseases 
(OND, n=12) and a cohort of healthy volunteers not suffering from any known 
infectious or inflammatory disorder (HC, n=40). Table 1 summarizes the 
demographic characteristics of patients and controls. Supplementary Table 1 
summarizes the diagnosis of patients with OIND and OND. This study was 
approved by the local ethics committee (Ethik-Kommission der Ärztekammer 
Hamburg), and written informed consent was obtained from all patients and 
controls before blood was drawn. 
2.2 Quantification of circulating NETs and dsDNA in serum samples 
Detection of myeloperoxidase (MPO) associated with DNA was used to 
quantify circulating NETs. MPO-DNA complexes in serum samples were 
quantified as previously described (Kessenbrock et al., 2009). Briefly, 5 µg/ml 
of mouse anti-human myeloperoxidase (MPO)-specific capture antibody (AbD 
SeroTec, Duesseldorf, Germany) was coated to 96-well plates. After blocking 
with 1% BSA, serum samples were added together with a peroxidase-labeled 
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anti-DNA monoclonal antibody (component 2 of the Cell Death ELISA kit, 
Roche). After 2 h of incubation, the peroxidase substrate was added 
according to manufacturer’s instructions. Absorbance was measured at 405 
nm using a µQuant microplate reader (Bio-Tek, Winooski, VT, USA). Total 
dsDNA in serum was quantified using Picogreen dsDNA kit (invitrogen, 
GIBCO, Paisley, UK) as previously described (Fuchs et al., 2007). 
2.3 Neutrophil purification and in vitro stimulation 
Neutrophils from RRMS patients and HC were isolated from freshly drawn 
peripheral blood using Dextran-Ficoll, as described previously (Weiss et al., 
1985). Briefly, erythrocytes were sedimented for 30 minutes in Hank’s 
balanced salt solution (HBSS) (Invitrogen GIBCO, Paisley, UK) containing 3% 
pure Dextran 200 (Serva, Heidelberg, Germany). The top phase was carefully 
layered onto 3 ml of LSM 1077 Ficoll solution (PAA Laboratories GmbH, 
Pasching, Austria) and centrifuged for 30 minutes at 2000 rpm without brakes. 
After centrifugation, the supernatant was discarded and the pellet washed. 
Remaining erythrocytes were lysed by adding 5 ml ice-cold H2O for 20 sec. 
Neutrophil purity and viability was ≥97% and ≥95% respectively as assessed 
by expression of the neutrophil-specific marker CD16b and trypan blue 
exclusion as already described (Naegele et al., 2012). 
Purified neutrophils were resuspended in HBSS (Invitrogen) medium 
supplemented with 10 mM Hepes (Invitrogen). 5 x 105-106 neutrophils/ml 
were seeded into tissue culture plates on glass coverslips (Menzel, GmbH, 
Braunschweig, Germany) pretreated with 0.001 % poly-L-lysine (Sigma-
Aldrich, Steinheim, Germany). Neutrophils were stimulated with 25 nM PMA 
(Sigma-Aldrich) for 3 h. 
2.4 Isolation and quantification of NETs 
NETs released by activated neutrophils were digested with 10 U/ml 
micrococcal nuclease (MNase, Worthington Biochemical Corp. Lakewood, 
NJ) as previously described (Urban et al., 2009). NETs (MPO-DNA 
complexes) in supernatants were quantified using a capture ELISA as 
previously described (Kessenbrock et al., 2009). Absorbance was measured 
at 405 nm using a µQuant microplate reader (Bio-Tek, Winooski, VT, USA). 
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2.5 Protein- and cytokine determinations 
C-reactive protein (CRP) and IL-6 levels in serum samples were measured at 
the central laboratory, University Medical Center Hamburg-Eppendorf. IL-8, 
platelet factor 4 (PF4), beta-thromboglobulin (beta-TG) and sVE-cadherin 
levels in serum samples were measured by ELISA using the following kits: 
Human IL-8 CytoSet™ (Biosource, Invitrogen), sCD144 (sVE-Cadherin) 
ELISA kit (PromoKine, PromoCell, GmbH, Germany), Asserumchrom® βTG 
(Diagnostica Stago, Parsippany, NJ) and RayBio® Human PF-4 ELISA kit 
(RayBiotech, Norcross, GA). Reactions were performed according to the 
manufacturer’s instructions. 
2.6 Blood cell counts 
Peripheral blood was collected in EDTA-tubes and cell counts determined 
using an AcT Diff Coulter Counter (Beckman Coulter, Inc. Fullerton, CA) 
standardized with Coulter 4C-ES Cell Control (Beckman Coulter). 
2.7 Intracellular cytokine staining 
For intracellular cytokine staining, PBMCs were stimulated with PMA (50 
ng/ml, Sigma) and ionomycin (1 µg/ml, Sigma) in the presence of Brefeldin A 
(10 µg/ml, eBioscience) for 5 h. Next, cells were stained with LIVE/DEAD 
Fixable Dead Cell Stain Kit (AmCyan, Molecular Probes, Invitrogen), fixed and 
permeabilized with the corresponding buffers (eBioscience), and stained for 
CD3 (PE, DakoCytomation, Denmark), CD8 (PB, DakoCytomation, Denmark), 
IFNγ (FITC, BDPharmingen), IL-4 (PE-Cy7, eBioscience) and IL-17A (Alexa 
Fluor-647, eBioscience) at room temperature. Sample acquisition was done 
with a LSR-II (BD) flow cytometer and data analyzed with FACS Diva (BD) 
and the FlowJo (Tree Star, Inc.) software packages. 
2.8 Characterization of peripheral blood monocytes and dendritic cells  
Human PBMCs were isolated from peripheral venous blood by density 
gradient and stained with anti-CD14 (Pacific Blue, Becton Dickinson, BD, 
Franklin Lakes, NJ), anti-CD16 (APC-Cy7, Biozol, Germany), anti-CD19 
(Pacific Blue, BD) and anti-CD40 PE (PE, Miltenyi, Biotec, GmbH, Germany) 
for the characterization of monocytes and with anti-CD14, anti-CD19, anti-
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CD40, anti-CD86 (FITC, Dako), anti-CD141 (APC, Miltenyi), anti-CD303 
(APC, Miltenyi) and anti-CD1c (APC, Miltenyi) for the characterization of 
dendritic cells. Corresponding isotype controls were also measured. Sample 
acquisition was done with a LSR-II (BD) flow cytometer and data analyzed 
with FACS Diva (BD) and FlowJo (Tree Star, Inc.) software packages. 
2.9 Autoantibodies determination 
Anti-nuclear antibodies (ANAs), anti-neutrophil cytoplasmic antibodies 
(ANCAs) and anti-ds DNA titer in serum samples were determined using 
commercial assays (Euroimmun, Luebeck, Germany). 
2.10 Statistical analysis 
Statistical analyses were performed with Prism 5.02 (GraphPad Software Inc., 
San Diego, CA). Parametric tests were applied for two-group comparisons 
using unpaired t-tests with two-tailed p-values. Comparisons of three groups 
and more were assessed by one-way ANOVA with Bonferroni’s correction for 
multiple comparisons. P-values < 0.05 were considered statistically 
significant.  
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3-Results 
3.1 Gender differences in circulating levels of NETs in serum of RRMS 
patients 
In order to explore whether higher levels of circulating NETs are a unique 
feature of RRMS patients, we quantified MPO-DNA complexes in serum of 
other MS and non-MS patients including CIS (n=126), PPMS (n=21), OIND 
(n=5) and OND (n=10) patients. Significant differences in the level of MPO-
DNA complexes were observed in RRMS and OIND patients but not in CIS, 
PPMS or OND patients compared with HC (Fig. 1A). The amount of MPO-
DNA complexes in serum of RRMS patients showed strong inter-individual 
variability, with optic density (OD) at 405 nm ranging from 0.107 to 2.288. In 
order to facilitate analysis, we have arbitrarily defined a threshold of OD > 0.3 
to identify patients with high content of MPO-DNA complexes in serum. 17.7 
% of RRMS and 60% of OIND patients showed OD > 0.3, i.e. high levels of 
MPO-DNA complexes in serum. The percentage of HC (7.5 %), CIS (8.8 %), 
PPMS (4.7 %) or OND (10 %) patients belonging to this group was lower (Fig. 
1A). 
We also analyzed whether MPO-DNA complexes were present in CSF 
samples of CIS (n=20), RRMS (n=21), PPMS (6), OIND (5) and OND (10) 
patients. No MPO-DNA complexes were detectable in CSF (Fig. 1B). 
MPO-DNA complexes did not correlate with age (Fig. 1C) but unexpectedly 
were significantly higher in males compared with females (Fig. 1D). When the 
different groups of patients and HC were analyzed independently, sex-specific 
differences were statistically significant only in RRMS patients. 12.1% of 
female RRMS patients showed OD > 0.3, i.e. high levels of MPO-DNA 
complexes in serum, compared to 26.2% of male RRMS patients (Fig. 1D). 
Interestingly, our previous observation that neutrophils in RRMS patients are 
more numerous and exhibit a primed state does not seem to underlie the 
gender-specific differences in circulating levels of MPO-DNA complexes, 
since neutrophil counts, neutrophil expression of fMLP receptor (FPR1), IL-8 
receptor (CXCR1), TLR2, CD43 and CD63, all markers of neutrophil priming 
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and significantly higher in RRMS patients (Naegele et al., 2012), did not show 
gender-specific differences (Supplementary Fig. 1). 
3.2 Gender differences in NETs formation and degradation 
In order to explore whether NETosis can be more easily induced in male 
RRMS neutrophils, which could explain the gender-specific differences in 
MPO-DNA complexes in serum, we compared the ability of purified 
neutrophils from female and male RRMS patients and HC to release NETs in 
vitro. Purified neutrophils from female (n=20) and male (n=10) RRMS patients 
and female (n=33) and male (n=22) HC were stimulated in vitro with PMA and 
NETs were isolated and quantified using an MPO-DNA capture ELISA. 
Results are summarized in Figure 2A. No significant differences in NET 
formation were observed between neutrophils from female and male RRMS 
patients and HC, although females from both groups showed a tendency to 
release more MPO-DNA complexes than males. 
Next, in order to examine whether gender differences in DNAse activity could 
be involved in the high level of MPO-DNA complexes in male RRMS patients, 
we have compared cell-free dsDNA in serum of pre-selected groups of female 
and male RRMS and CIS patients, each group containing a similar number of 
individuals with high (OD > 0.3, RRMS female n=9 and male n=9, CIS female 
n=7, males=7) and low (OD < 0.2, RRMS female n=9 and male n=9, CIS 
female n=6, males=8) levels of MPO-DNA complexes (Fig. 2B). No correlation 
between NETs and dsDNA was observed in these groups of patients, but 
interestingly, male RRMS- but not CIS patients showed a significantly higher 
level of cell free dsDNA in serum compared with females (Fig. 2B). When the 
level of dsDNA in female and male RRMS and CIS patients containing high or 
low levels of MPO-DNA complexes was compared (Fig. 2C), a significantly 
higher level of dsDNA was found in serum of male RRMS with high MPO-
DNA complexes compared with females with low complexes, while no 
differences were found in CIS patients. 
3.3 Circulating NETs in serum and disease activity 
In order to characterize circulating levels of NETs in serum of RRMS patients, 
we measured MPO-DNA complexes in different serum samples obtained from 
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8 individual patients (4 females and 4 males) at different time points (Fig. 3A). 
We found that high levels of NETs (OD > 0.3) were not stable but fluctuated 
over time. In some patients the analyzed serum samples never reached an 
OD > 0.3, indicating low levels of circulating NETs. Interestingly, patient 2 
showed a very high level of circulating NETs over a period of 30 months. 
With the purpose to examine whether these fluctuations were related with 
disease activity, we compared serum samples of females and males CIS and 
RRMS patients in remission and relapse (CIS females n=40 remission and 38 
relapse, CIS males n=29 remission and 19 relapse; RRMS females n=63 
remission and 43 relapse, RRMS males n=36 remission and 26 relapse). No 
significant differences in the amounts of MPO-DNA complexes were observed 
between patients in remission and relapse (Fig. 3B). We also analyzed 22 
RRMS patients, from whom paired serum samples corresponding to relapse 
and remission were available (Fig. 3C). In most patients higher or similar 
amounts of MPO-DNA complexes were detected in relapse while only in a few 
patients the amount was higher during remission. 
3.4 Putative triggers of NET formation in RRMS patients 
To address a putative link between NETs release and inflammation, we 
compared the level of serum IL-8 as an indicator of inflammation in pre-
selected groups of female and male RRMS patients with either high (OD > 
0.3, females n=9, males n=9) or low (OD < 0.2, females n=9, males n=9) 
levels of MPO-DNA complexes. As shown in Figure 4, no significant 
differences were observed between the different groups of patients. We also 
explored a putative role of infections in NETs release, by measuring C-
reactive protein (CRP) and IL-6. CRP is an acute-phase protein that rises in 
response to inflammation, and IL-6 is also an important mediator of acute-
phase responses. No significant differences in CRP or IL-6 levels between the 
different groups of patients were found (Fig. 4). Finally, we also examined a 
putative role of platelet and endothelial activation in NETosis by measuring 
the levels of platelet activation factor (PF4) and soluble beta-thromboglobulin 
(beta-TG) (Fig. 4) as markers of platelet activation (Kaplan and Owen, 1981; 
Stuckey et al., 1992) and soluble sVE cadherin (CD144, Fig. 4) as marker of 
endothelial activation and damage (Vestweber, 2008). No significant 
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differences in PAF, beta-TG or sVE cadherin levels between the different 
groups of patients were observed. 
3.5 Circulating NETs and peripheral blood lymphocytes 
Next, in order to explore a putative role of NETs in gender-specific differences 
in MS pathogenesis, we examined whether gender as well as the level of 
MPO-DNA complexes in serum have an effect on the circulating number of 
lymphocytes. First we compared the absolute lymphocyte counts in whole 
blood of females and males RRMS and HC (RRMS females n=35, males 
n=20; HC females n=25, males n=15), and no differences were found (Fig. 
5A). Then we measured absolute lymphocyte counts in female and male 
RRMS patients with high (OD > 3; females n=12, males n=9) and low (OD < 
0.2; females n=13, males n=10) MPO-DNA complexes in serum. Again no 
significant differences were found between the different groups (Fig. 5B). 
Circulating lymphocytes were further characterized by flow cytometry for a 
putative effect of gender and circulating MPO-DNA complexes on their 
functional phenotype. The percentages of CD8+ IFNγ-producing cells as well 
as of CD4+ Th1 (IFNγ-producing), Th2 (IL-4-producing) or Th17 (IL-17-
producing) cells were measured by intracellular cytokine staining in PBMCs of 
female and male RRMS patients with high (OD > 3; females n=8, males n=8) 
and low (OD < 0.2; females n=8, males n=8) MPO-DNA complexes in serum. 
No differences in the percentage of any of these T cell populations were found 
between the different groups of patients (Fig. 5C and D). 
3.6 Circulating NETs and peripheral blood dendritic cells 
Since it has been demonstrated that NETs can activate DCs, we also 
examined whether gender and the level of MPO-DNA complexes in serum 
have an effect on circulating DCs. We measured by flow cytometry the 
percentages of plasmacytoid, myeloid type 1 and myeloid type 2 DCs as well 
as their expression of CD40 and CD86 in female and male RRMS patients 
with high (OD > 0.3; females n=15, males n=13) and low (OD < 0.2; females 
n=14, males n=13) MPO-DNA complexes in serum (Fig. 6). We did not find 
significant differences in the percentage of any of these DC populations nor in 
their activation state between the different groups of patients. 
Circulating NETs in MS patients 
 14 
3.7 Circulating NETs and peripheral blood monocytes 
Subsequently, we also examined whether gender and level of MPO-DNA 
complexes in serum have an effect on circulating monocytes. First, we 
compared the absolute monocyte counts in whole blood of females and males 
RRMS and HC (RRMS females n=35, males n=20; HC females n=25, males 
n=15), and no differences were found (Fig. 7A). Then we measured absolute 
monocyte counts in female and male RRMS patients with high (OD > 3; 
females n=12, males n=9) and low (OD < 0.2; females n=13, males n=10) 
MPO-DNA complexes in serum. Unexpectedly, significantly higher monocyte 
counts were found in RRMS patients with high MPO-DNA complexes in 
serum, and interestingly the strong difference was observed between males 
with high and females with low MPO-DNA complexes in serum (Fig. 7B). In 
order to better understand the putative effect of gender and NETs on 
monocyte expansion, we also measured by flow cytometry in PBMCs the 
percentage of classical, intermediate and non-classical monocytes as well 
their expression of CD40 in female and male RRMS patients with high (OD > 
0.3; females n=10, males n=7) and low (OD < 0.2; females n=9, males n=7) 
MPO-DNA complexes in serum. We did not find significant differences in the 
percentage of any of these monocyte populations and neither regarding their 
activation state (Fig. 7C). 
3.8 Autoantibodies in RRMS patients with NETs in serum 
Finally, since pathogenic antinuclear (ANA), ANCA and anti-dsDNA auto-
antibodies have been associated with abnormal NETs clearing and NETosis 
in SLE (Knight and Kaplan, 2012), anti-dsDNA auto-antibodies are more 
prevalent among male SLE patients, and further since ANCAs have been 
found elevated in patients with the optico-spinal form of MS in Japan 
(Fukazawa et al., 1996), we measured ANA, cANCA, pANCA and anti-dsDNA 
antibody levels in serum samples of female and male RRMS patients with 
high (OD > 3; females n=6, males n=5) and low (OD < 0.2; females n=6, 
males n=4) MPO-DNA complexes. No anti-dsDNA nor cANCA autoantibodies 
were detected in any sample and for ANA and cANCA, although a tendency 
to higher levels in males was observed, differences did not reach significance 
(Table 2). 
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4-Discussion 
NETs are extracellular chromatin fibers bound to granular, nuclear and 
cytoplasmic proteins that despite their importance as effective antimicrobial 
first line defense mechanism, also occur in various clinical settings in the 
absence of microbial infections and might be associated with 
pathophysiological conditions (Logters et al., 2009). In a previous study 
(Naegele et al., 2012), we demonstrated that neutrophils in RRMS patients 
are more numerous and exhibit a primed state. Among the features of 
neutrophils in these patients, we found significantly higher levels of NETs in 
the serum and speculated that these may be involved in MS pathogenesis. To 
examine this issue in depth, we analyzed here a large cohort of MS patients 
including patients suffering from subforms of MS other than RRMS, and found 
that only a small subset of RRMS patients have elevated circulating NETs. In 
view of the fact that women of reproductive age have a higher systemic 
neutrophil count compared with men and that RRMS affects women about 
twice as often as men we then examined whether the level of NETs in serum 
as well as neutrophil counts and primed phenotype in RRMS patients were 
higher in females. Unexpectedly, our results demonstrate that the subset of 
RRMS patients with high NETs in serum was significantly enriched in male 
patients while no gender specific differences were observed in neutrophil 
counts and primed state. Although higher circulating NET levels do not seem 
to be a general feature of RRMS patients, they might still be relevant in the 
above subset of RRMS patients and underlie gender-specific differences in 
MS pathogenesis. MS is a highly heterogeneous disease most likely involving 
very diverse pathomechanisms. Neutrophils are normally not present in the 
CNS of MS patients, and consistent with this notion we did not detect NETs in 
CSF samples from these patients. Considering the potential dangers 
associated with the indiscriminate histotoxic potential of neutrophils there may 
be active mechanisms preventing their entry into the vulnerable CNS 
compartment. However, these cells are likely to play a role in opening the 
blood brain barrier, particularly via NETosis, and this potential mechanism 
deserves further investigation. 
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The higher circulating NETs in a subset of RRMS patients and particularly in 
males could reflect an alteration in NET formation and/or in NET degradation. 
Neutrophils in RRMS patients are primed and can easily be activated 
(Naegele et al., 2012), which could explain higher NETosis in RRMS patients. 
However, our observation that granulocyte counts as well as the neutrophil 
primed state did not show gender-specific differences argues against this 
hypothesis. To explore further this possibility, we also analyzed NETosis in 
vitro using purified neutrophils from female and male RRMS patients and HC. 
We did not find differences in NETosis between purified neutrophils from 
RRMS and HC and neither gender-specific significant differences. In contrast, 
male RRMS patients showed significantly higher cell-free dsDNA in serum 
compared with female patients suggesting a putative abnormal DNAse activity 
that might underlie the higher circulating NETs levels in male RRMS patients. 
Interestingly, in SLE, in which women are affected about 10 times more 
frequently than men, it is interesting to note that male gender has been 
associated with more severe disease and with higher prevalence of 
pathogenic anti-dsDNA autoantibodies (Freire de Carvalho et al., 2010; Lu et 
al., 2010; Molina et al., 1996). Similarly, RRMS affects women about twice as 
often as men, and overall male gender has also been associated with worse 
prognosis. Although some small studies reported that men with MS are prone 
to develop less inflammatory but more destructive lesions than women 
(Pozzilli et al., 2003), have less T2 and gadolinium(Gd)-enhancing lesions 
(Weatherby et al., 2000) but more T1 lesions (van Walderveen et al., 2001) 
and more brain atrophy (Antulov et al., 2009), gender-specific MRI differences 
have not been confirmed by large studies (Fazekas et al., 2009). However, 
gender appears to influence disability during the early phase of RRMS. When 
males are compared with females, they do not show differences at the age of 
RRMS onset, but females progress more slowly and thus are overall older 
when they reach a disability status scale of 3 (Leray et al., 2010). Since 
disability evolution in RRMS correlates with axonal injury and this in turn 
correlates with inflammation, all these data suggest that the nature of 
inflammation and/or a higher vulnerability of CNS tissue in RRMS males might 
underlie the worse prognosis in these patients. Higher circulating NETs levels 
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might prime T cells and other immune cell types as well as facilitate their 
migration through the blood brain barrier and, as a consequence, lead to more 
destructive neuroinflammatory processes in male RRMS patients. 
In order to understand better the potential causes of NETosis in RRMS 
patients we have performed a systematic and in depth characterization of 
these patients. Our data show that high levels of NETs are not stable in 
serum, but fluctuate over time. While this might indicate an association with 
disease activity, which comes and goes in MS, we could not demonstrate a 
correlation between relapses and higher circulating NETs in serum. 
Regarding potential triggers, we could not either demonstrate an involvement 
of inflammation, infection, platelet nor endothelial activation. One important 
question to consider in the interpretation of these results is the stability and 
half-life of MPO/DNA complexes in serum. Different from free DNA that is 
easily digested by DNAses, MPO-DNA complexes appear to be much more 
stable, and consequently their presence may not always indicate recent 
NETosis. This open issue might be one of the reasons for our difficulties to 
identify triggers of NETs. 
Further we have addressed a putative role of these complexes in RRMS 
pathogenesis and gender-specific differences by systematically characterizing 
circulating lymphocytes, DCs and monocytes. Unfortunately, the analysis of 
circulating lymphocytes and DCs did not provide information regarding a 
putative role of NETs in MS pathogenesis and neither regarding gender-
specific differences. Unexpectedly, the analysis of circulating monocytes 
showed significant higher monocyte counts in whole blood of RRMS patients 
with higher circulating NETs and particularly in male patients. The phenotypic 
characterization of classical, intermediate and non-classical monocytes in 
these patients did not allow us to identify the monocyte population expanded, 
which suggests that we are either missing other monocyte populations or that 
our cell counter-based monocyte counts enumerate as monocytes another 
cell type with similar physical features. The identification and characterization 
of this cell population expanded in RRMS with high NETs requires further 
investigation. 
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Finally, we also examined a putative link between NETs in serum and 
autoantibody production in RRMS patients. ds-DNA auto-antibodies and 
cANCA were not detected in any sample. Regarding ANA and pANCA, 
although the differences were not significant, the tendency to higher level in 
males might deserve further investigation. As mentioned above with respect 
to triggers of NETs, the lack of information concerning the exact time point of 
NETosis most likely hinders the search for a putative role of these complexes 
in RRMS pathogenesis. 
The well documented role of NETs in the pathogenesis of some autoimmune 
diseases, their ability to modulate T cell immunity and our previous 
observation that higher levels of NETs in serum characterize a subset of 
RRMS patients encouraged us to analyze in detail whether abnormally high 
levels of NETs may play a role in certain aspects of this T cell-mediated 
autoimmune disease. As discussed above, the low frequency of RRMS 
patients with high levels of circulating NETs as well as the results from our 
characterization of these patients argue against a major role of NETosis in 
disease pathogenesis. However, our observation that individuals with high 
level of circulating NETs were significantly higher among RRMS patients than 
among HC or patients with other MS subforms, and more importantly that the 
frequency of males belonging to this subset was significantly higher than of 
females, suggests that NETosis might be responsible for some of the gender- 
specific differences in this disease and be involved in some aspects of MS 
pathogenesis such as opening of the blood brain barrier. Further investigation 
of gender-specific differences in NETosis using other methodological 
approaches might clarify its role in MS pathomechanisms and -heterogeneity. 
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Figure legends 
Figure 1. Gender differences in circulating levels of NETs in serum of 
RRMS patients. A) Quantification of MPO-DNA complexes in serum samples 
of HC (n=40), CIS (n=126), RRMS (n=168), PPMS (n=21), OIND (n=5) and 
OND (n=10) patients. An arbitrary threshold of OD > 0.3 to differentiate 
samples with high MPO-DNA complexes is shown (dotted line). Percentage of 
donors/patients with OD > 0.3, the mean OD as measured by capture ELISA 
and the statistical significance are shown. (* p<0.05). B) Quantification of 
MPO-DNA complexes in CSF samples from CIS (n=20), RRMS (n=21), 
PPMS (n=6), OIND (n=5) and OND (n=10) patients. C) Correlation between 
age and MPO-DNA complexes in all serum samples. D) Quantification of 
MPO-DNA complexes in serum samples of all females (n=225) and males 
(n=149), of HC females (n=20) and males (n=20), of CIS females (n=78) and 
males (n=50), of RRMS females (n=107) and males (n=61) and of PPMS 
females (n=10) and males (n=9). Percentage of donors/patients with OD > 
0.3, the mean optical density and statistical significance are shown. (* 
p=0.0113, **p=0.0058). 
Figure 2. Gender differences in NETs formation and degradation. A) 
Quantification of MPO-DNA complexes released in vitro by purified 
neutrophils from female (n=33) and male (n=22) HC and female (n=20) and 
male (n=8) RRMS patients after stimulation with 25 nM PMA. The mean 
stimulation index (SI) is shown. (SI= OD measured by capture ELISA in 
stimulated neutrophils / OD in unstimulated neutrophils. B) Quantification of 
MPO-DNA complexes in serum samples from pre-selected groups of female 
and male RRMS patients and CIS patients each group containing a equal 
number of individuals with high (OD > 0.3, RRMS female n=9 and male n=9, 
CIS female n=7, males=7) or low (OD < 0.2, RRMS female n=9 and male 
n=9, CIS female n=6, males=8) levels of MPO-DNA complexes (upper 
graphs). dsDNA (ng/ml) quantified using Picogreen in the same groups of 
female and male patients (lower graphs). Mean and statistical significance are 
shown. (**p=0.0046). C) dsDNA (ng/ml) quantified using Picogreen in the 
same groups of female and male patients with high (OD>0.3) and low 
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(OD<0.2) MPO DNA complexes. Mean and statistical significance are shown. 
(**p<0.01). 
Figure 3. Circulating NETs in serum and disease activity. A) 
Quantification of MPO-DNA complexes in serum samples of 8 RRMS patients 
(4 females/4 males) obtained at different time points. B) Quantification of 
MPO-DNA complexes in serum samples of CIS females (n=40 remission and 
38 relapse), CIS males (n=29 remission and 19 relapse), RRMS females 
(n=63 remission and 43 relapse) and RRMS males (n=36 remission and 26 
relapse) C) Quantification of MPO-DNA complexes in serum samples from 
female (upper graphs) and male (lower graphs) RRMS patients for whose 
paired samples in remission and relapse were available. The left graphs 
shows patients with higher MPO-DNA complexes in relapse than in remission, 
while the right graph shows patients with higher MPO-DNA complexes in 
remission than in relapse. An arbitrary threshold of OD > 0.3 to differentiate 
samples with high MPO-DNA complexes is shown in all graphs (dotted line). 
Figure 4. Putative triggers of NET formation in RRMS patients. A) IL-8, 
CRP, IL-6, PF4, beta-TG and sVE cadherin quantification in serum samples of 
pre-selected groups of female (upper graphs) and male (lower graphs) RRMS 
patients with high (OD > 0.3, female n=9, male n=9) and low (OD < 0.2, 
female n=9, male n=9) MPO-DNA complexes. The mean is shown in all 
graphs. 
Figure 5. Circulating NETs and peripheral blood lymphocytes. A) 
Absolute peripheral blood counts of lymphocytes obtained using a coulter 
counter in female and male HC and RRMS patients (RRMS females n=35, 
males n=20; HC females n=25, males n=15). B) Absolute peripheral blood 
lymphocyte counts in female and male RRMS patients with high (OD > 3; 
females n=12, males n=9) and low (OD < 0.2; females n=13, males n=10) 
MPO-DNA complexes in serum. Mean ± SEM are shown. Frequency (%) 
determined by flow cytometry of CD3+CD8+ and CD3+CD8+ IFNγ-producing T 
cells (CD8+ IFNγ+) (C), and CD3+CD4+, Th1 (CD3+CD4+ IFNγ+ IL-4- IL-17A-), 
Th2 (CD3+CD4+ IFNγ- IL-4+) and Th17 (CD3+CD4+ IFNγ- IL-17A+) T cells (D) 
in PBMCs of female and male RRMS patients with high (OD > 0.3, female 
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n=8, male n=8) and low (OD < 0.2, female n=8, male n=8) MPO-DNA 
complexes in serum. Mean is shown in all graphs. 
Figure 6. Circulating NETs and peripheral blood dendritic cells. Gating 
strategy used to identify mDCs type 1 (CD1c+), mDCs type 2 (CD141+) and 
pDCs (CD303+) (upper dot plots). Frequency (%, upper graphs) of the 
different DCs and CD40 and CD86 expression (MedFI, lower graphs) in 
PBMCs of female and male RRMS patients with high (OD > 0.3; females 
n=15, males n=13) and low (OD < 0.2; females n=14, males n=13) MPO-DNA 
complexes in serum. Mean is shown in all graphs. 
Figure 7. Circulating NETs and peripheral blood monocytes. A) Absolute 
peripheral blood counts of monocytes obtained using a coulter counter in 
female and male HC and RRMS patients (RRMS females n=35, males n=20; 
HC females n=25, males n=15). B) Absolute peripheral blood monocyte 
counts in female and male RRMS patients with high (OD > 3; females n=12, 
males n=9) and low (OD < 0.2; females n=13, males n=10) MPO-DNA 
complexes in serum. Mean ± SEM and statistical significance are shown. 
(*p=0.0124; ***p<0.001). C) Frequency (%, upper graphs) of classical, 
intermediate and non-classical monocytes and CD40 expression (MedFI, 
lower graphs) in PBMCs of female and male RRMS patients with high (OD > 
0.3; females n=10, males n=7) and low (OD < 0.2; females n=9, males n=7) 
MPO-DNA complexes in serum. Mean is shown in all graphs. 
 
Table 1. Demographic characteristics of MS patients and controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group n F M F:M Mean Age  ± SD 
CIS 126 78 48 1.6 33.9 ± 8.8 
• CIS remission 76 48 28 1.7 35 ± 9.4 
• CIS relapse 50 30 20 1.5 32.3 ± 7.6 
RRMS 168 106 62 1.7 36.5 ± 7.9 
• RRMS remission 99 63 36 1.7 37.1 ± 7.5 
• RRMS relapse 69 43 26 1.6 35.7 ± 8.5 
PPMS 21 11 10 1.1 39.3 ± 6.6 
OIND 5 3 2 1.5 47.8 ± 20.5 
OND 10 5 5 1 45.3 ± 11 
HC 40 20 20 1 32.2 ± 7.3 
Table 2. Autoantibodies in female and male RRMS patients with low and high MPO-DNA 
complexes in serum 
 
GENDER OD (MPO-
DNA) 
ANA cANCA pANCA Anti-dsDNA 
FEMALES           
 0,12 neg neg neg neg 
 0,125 neg neg neg neg 
 0,187 pos (1/320) neg neg neg 
 0,11 pos (1/1000) neg neg neg 
 0,126 neg neg neg neg 
 0,135 neg neg neg neg 
      
MALES           
 0,121 pos (1/320) neg pos (IgG 1/10) neg 
 0,131 neg neg neg neg 
 0,155 pos (1/1000) neg pos (IgG 1/10) neg 
 0,21 pos (1/1000) neg neg neg 
           FEMALES      
 0,413 neg neg neg neg 
 0,477 neg neg neg neg 
 0,779 neg neg neg neg 
 0,901 neg neg neg neg 
 1,291 neg neg pos (IgG 1/10) neg 
 1,439 neg neg neg neg 
MALES           
 0,451 neg neg neg neg 
 0,491 neg neg neg neg 
 0,569 pos (1/320) neg neg neg 
 0,782 pos (1/320) neg neg neg 
 2,143 neg neg pos (IgG 1/10) neg 
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Supplementary Table-1. Diagnose of patients with inflammatory neurological diseases other 
than MS (OIND) and with non-inflammatory neurological diseases (OND) 
Conditi
on 
Diagnose 
OIND (Autoimmune) uveomeningeal syndrome 
OIND Idiopathic trigeminal neuralgia (left-sided) 
OIND Neuroborreliosis 
OIND Neuro-Behçet's disease 
OIND Paraneoplastic mixed axonal-demyelinating sensory-motor 
neuropathy (due to adenocarcinoma of the gastric cardia) 
OND Shoulder pain of unknown etiology 
OND Optical atrophy (suspected Leber's hereditary optic 
neuropathy) 
OND Chronic musculoskeletal pain of unknown etiology 
(suspected psychosomatic presentations) 
OND Muscle atrophy of unknown etiology 
OND Hypokinetic-rigid idiopathic Parkinson’s disease 
OND Tinnitus of unknown etiology 
OND Monoparesis of the right hand, most likely due to cerebral 
ischemia (underlying severe cerebral microangiopathy) 
OND Suspected myoclonic epilepsy with ragged red fiber 
(MERRF) syndrome 
OND distal paraesthesia of unknow etiology 
OND migraine with aura 
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